2 Notes to the financial statements
Cash and cash equivalent
CHF 1 000 | 31.12.2023 | 31.12.2022 | ||
Due from banks | 450 | 1 239 | ||
Total | 450 | 1 239 |
Other short-term receivables
CHF 1 000 | 31.12.2023 | 31.12.2022 | ||
Due from group companies | 5 712 | 3 500 | ||
Due from third parties | 7 | 22 | ||
Total | 5 719 | 3 522 |
Other short-term receivables from group companies include short-term loans and bore interest of 1.5% in the financial year (2022: 0.25%). The recorded interest is shown in the position «Finance income».
Participations
31.12.2023 | 31.12.2022 | |||||||||||||
Company | Domicile | Purpose | Currency | Share capital/Nominal capital | Capital | Voting rights | Capital | Voting rights | ||||||
Bellevue Asset Management AG | Küsnacht, Switzerland | Asset Management | CHF | 1 750 000 | 100% | 100% | 100% | 100% | ||||||
Bellevue Asset Management (Deutschland) GmbH | Frankfurt am Main, Germany | Asset Management | EUR | 540 000 | 100% | 100% | 100% | 100% | ||||||
Bellevue Asset Management (UK) Limited | London, UK | Asset Management | GBP | 50 000 | 100% | 100% | 100% | 100% | ||||||
Asset Management BaB N.V. | Curaçao | Asset Management | USD | 6 001 | 100% | 100% | 100% | 100% | ||||||
Bellevue Research Inc. | New York, USA | Research | USD | 100 | 100% | 100% | 100% | 100% | ||||||
BB Biotech Ventures GP | Guernsey | Investment Advisor | GBP | 10 000 | 100% | 100% | 100% | 100% | ||||||
BB Pureos Bioventures GP Limited | Guernsey | Investment Advisor | GBP | 60 000 | 99% | 99% | 99% | 99% | ||||||
Bellevue Private Markets AG | Zug, Switzerland | Investment Advisor | CHF | 1 000 000 | 100% | 100% | 100% | 100% | ||||||
adbodmer AG | Zug, Switzerland | Investment Advisor | CHF | 100 000 | 100% | 100% | 100% | 100% | ||||||
Bellevue Komplementär AG | Küsnacht, Switzerland | Asset Management | CHF | 200 000 | 100% | 100% | 100% | 100% | ||||||
Bellevue Private Markets Management I S.à.r.l. | Luxembourg | Asset Management | EUR | 12 000 | 100% | 100% | 100% | 100% | ||||||
As a rule, participations are valued individually. For participations that are already managed and assessed together as an economic business unit within the company, the impairment test of the participations is performed analogously to the IFRS consolidated financial statements at the level of the economic business units.
Short-term interest-bearing liabilities
CHF 1 000 | 31.12.2023 | 31.12.2022 | ||
Due to group companies | 2 304 | – | ||
Total | 2 304 | – |
Short-term interest-bearing liabilities to Group companies include short-term loans and bore interest of 1.5% in the financial year. The recorded interest is shown in the position «Finance expense».
Other short-term liabilities
CHF 1 000 | 31.12.2023 | 31.12.2022 | ||
Due to third parties | 11 | 94 | ||
Total | 11 | 94 |
Treasury Shares
Treasury shares are held directly by the Company. All transactions are carried out at market prices.
Average price in CHF | Number of shares | |||
Balance as of 1.1.2022 | 155 631 | |||
Purchases | 34.1625 | 294 750 | ||
Disposals | 36.4208 | – 208 305 | ||
Balance as of 31.12.2022 | 242 076 | |||
Purchases | 26.4317 | 214 649 | ||
Disposals | 29.3252 | – 151 252 | ||
Balance as of 31.12.2023 | 305 473 |